These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

964 related articles for article (PubMed ID: 17113978)

  • 1. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xenograft models for aromatase inhibitor studies.
    Brodie A; Sabnis G; Macedo L
    J Steroid Biochem Mol Biol; 2007; 106(1-5):119-24. PubMed ID: 17611101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic observations in MCF-7 aromatase xenografts.
    Brodie A; Jelovac D; Macedo L; Sabnis G; Tilghman S; Goloubeva O
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):884s-8s. PubMed ID: 15701882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stopping treatment can reverse acquired resistance to letrozole.
    Sabnis GJ; Macedo LF; Goloubeva O; Schayowitz A; Brodie AM
    Cancer Res; 2008 Jun; 68(12):4518-24. PubMed ID: 18559495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
    Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase inhibitors and breast cancer.
    Macedo LF; Sabnis G; Brodie A
    Ann N Y Acad Sci; 2009 Feb; 1155():162-73. PubMed ID: 19250202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
    McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
    Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors.
    Macedo LF; Sabnis G; Brodie A
    Cancer; 2008 Feb; 112(3 Suppl):679-688. PubMed ID: 18072255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
    Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
    Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
    Sabnis G; Schayowitz A; Goloubeva O; Macedo L; Brodie A
    Cancer Res; 2009 Feb; 69(4):1416-28. PubMed ID: 19190349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
    Sabnis G; Brodie A
    Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
    Brodie AH; Jelovac D; Long B
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):283-8. PubMed ID: 14623522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
    Belosay A; Brodie AM; Njar VC
    Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors and xenograft studies.
    Chumsri S; Sabnis GJ; Howes T; Brodie AM
    Steroids; 2011 Jul; 76(8):730-5. PubMed ID: 21420993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase resistance mechanisms in model systems in vivo.
    Brodie A; Macedo L; Sabnis G
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):283-7. PubMed ID: 19778610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
    Curley MD; Sabnis GJ; Wille L; Adiwijaya BS; Garcia G; Moyo V; Kazi AA; Brodie A; MacBeath G
    Mol Cancer Ther; 2015 Nov; 14(11):2642-52. PubMed ID: 26310543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
    Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
    Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.